RxDoctor Payments Data

Leonard di Vagno, MD

Interventional Cardiology · Rochelle Park, NJNPI 1851392435

Payments from drug & device makers

$7,433in general payments, 2019–2025

Across 465 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$908
  • Novartis$851
  • Amgen$739
  • Boston Scientific$659
  • Merck$396
  • Amarin Pharma, Inc.$337
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$7,30298%
  • Education$1152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,433 in reported general payments places this provider in the 35th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$90,873
Medicare patients
399
Services billed
1,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$330,473
EntrestoSacubitril/Valsartan114$158,780
Repatha SureclickEvolocumab112$97,416
XareltoRivaroxaban72$70,310
JardianceEmpagliflozin32$35,662
BrilintaTicagrelor24$30,910
Praluent PenAlirocumab40$27,560
FarxigaDapagliflozin Propanediol23$27,088
VascepaIcosapent Ethyl43$26,059
VerquvoVericiguat12$22,703
Icosapent Ethyl40$21,025
MultaqDronedarone Hcl12$20,827
Repatha PushtronexEvolocumab19$19,522
Ranolazine ErRanolazine146$16,963
EdarbiAzilsartan Medoxomil25$14,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$333$330,473285 claims
NovartisEntresto$851$158,780114 claims
Johnson & JohnsonXarelto$122$70,31072 claims
AstraZenecaBrilinta, Farxiga$908$57,99847 claims
Boehringer IngelheimJardiance$333$35,66232 claims
MerckVerquvo$396$22,70312 claims
Sanofi-aventis U.S. LLCMultaq$326$20,82712 claims
Arbor Pharmaceuticals, Inc.Edarbi$298$14,84125 claims
Kowa Pharmaceuticals America, Inc.Bystolic$81$1,96111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Rochelle Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →